Key result
Modern multi-drug lipid-lowering therapies and lipoprotein apheresis improved survival in 48 Canadian homozygous familial hypercholesterolemia patients followed for nearly 30 years.
Answers are grounded in this paper and cite their sources.
Reviews advances in homozygous familial hypercholesterolemia management, highlighting improved long-term survival while emphasizing earlier diagnosis and global treatment access.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Frederick J. Raal (2023) conducted an editorial in Homozygous familial hypercholesterolemia (HoFH) (n=48). Multi-drug lipid-lowering therapy and lipoprotein apheresis was evaluated on Survival and LDL-C lowering. Modern multi-drug lipid-lowering therapies and lipoprotein apheresis improved survival in 48 Canadian homozygous familial hypercholesterolemia patients followed for nearly 30 years.
Synapse has enriched 10 related papers. Consider them for comparative context: